Effect of F-1394, a potent and selective inhibitor of acyl- CoA:cholesterol acyltransferase (ACAT), on esterification of cholesterol and basolateral secretion of cholesteryl ester in Caco-2 cells

Folia Pharmacologica Japonica

Volumn 110, Issue 6, 1997, Pages 357-365

  Kusunoki, Jun ^a   Aragane, Katsumi ^a   Kitamine, Tetsuya ^a   Yamaura, Tetsuaki ^a   Ohnishi, Haruo ^a  

^a FUJIREBIO INC   (Japan)

Author keywords

ACAT; ACAT inhibitor; Caco 2 cells; Cholesteryl ester secretion; F 1394

Indexed keywords

1,3 BIS[[1 CYCLOHEPTYL 3 (4 DIMETHYLAMINOPHENYL)UREIDO]METHYL]BENZENE; 2 [3 (2,2 DIMETHYLPROPYL) 3 NONYLUREIDO]CYCLOHEXANE 1 YL 3 [N (2,2,5,5 TETRAMETHYL 1,3 DIOXANE 4 CARBONYL)AMINO]PROPIONIC ACID; 2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; 3 (2,4 DIFLUOROPHENYL) 1 HEPTYL 1 (4 NEOPENTYLBENZYL)UREA; ANTILIPEMIC AGENT; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER; CLOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MELINAMIDE; PRAVASTATIN; PROBUCOL; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; BASOLATERAL MEMBRANE; CELL STRAIN CACO 2; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HYPERLIPIDEMIA;

EID: 0031455483     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.110.357     Document Type: Article

References (34)

1. Chang TY and Doolittle GM: Acylcoenzyme A:cholesterol O-acyltransferase. In The Enzymes, Edited by Boyer PD, Vol 16, pp523-539, Academic Press, New York (1983)
2. Norum KR, Lilljeqvist A-C, Helgerud P, Normann ER, Mo A and Selbekk B: Esterification of cholesterol in human intestine: the importance of acyl-CoA:cholesterol acyltransferase. Eur J Clin Invest 9, 55-62 (1979)
3. Norum KR, Helgerud P and Lilljeqvist A-C: Enzymatic esterification of cholesterol in rat intestinal mucosa catalyzed by acyl-CoA:cholesterol acyltransferase. Scand J Gastroenterol 16, 401-410 (1981)
4. Krause BR, Pape ME, Kieft K, Auerbach B, Bisgaier CL, Homan R and Newton RS: ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet, marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance. Arterioscler Thromb 14, 598-604 (1994)
5. Huff MW, Telfold DE, Barrett PHR, Billheimer JT and Gillies PJ: Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler Thromb 14, 1498-1508 (1994)
6. Brown MS, Ho YK and Goldstein JL: The cholesterol ester cycle in macrophage foam cells. J Biol Chem 255, 9344-9352 (1983)
7. Brown MS and Goldstein JL: Lipoprotein metabolism in macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52, 223-261 (1985)
8. Silskovic DR and White AD: Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol Sci 12, 194-199 (1991)
9. Kusunoki J, Aragane K, Yamaura T and Ohnishi H: Studies on acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory effects and enzyme selectivity of F-1394, a pantotheic acid derivative. Jpn J Pharmacol 67, 195-203 (1995)
10. Kusunoki J, Aragane K, Kitamine T, Higashinakagawa S, Kase N, Yamaura T and Ohnishi H: Hypocholesterolemic action and prevention of cholesterol absorption via the gut by F-1394, a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in cholesterol diet-fed rats. Jpn J Pharmacol 69, 53-60 (1995)
11. Fogh J, Fogh JM and Orfeo T: One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59, 221-226 (1977)
12. Pinto M, Robine-Leon S, Appay M-D, Kedinger M, Triadou N, Dussaulx E, Lacroix B, Simon-Assmann P, Haffen K, Fogh J et al: Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47, 323-330 (1983)
13. Hughes TE, Sasak WV, Ordovas JM, Forte TM, Lamon-Fava S and Schaefer EJ: A novel cell line (Caco-2) for the study of intestinal lipoprotein synthesis. J Biol Chem 262, 3762-3767 (1987)
14. Traber MG, Kayden HJ and Rindler MJ: Polarized secretion of newly synthesized lipoproteins by the Caco-2 human intestinal cell line. J Lipid Res 28, 1350-1363 (1987)
15. Kashiwa M, Masuyama Y, Miyauchi H, Uchida T, Naganuma S, Kakuta H, Terada M, Kiriyama T, Matsuda K, Ito N et al: Pharmacological properties of YM-17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Jpn J Pharmacol 73, 41-50 (1997)
16. Field FJ, Albright E and Mathur S: Inhibition of acylcoenzyme A:cholesterol acyltransferase activity by PD128042: Effect on cholesterol metabolism and secretion in CaCo-2 cells. Lipids 26, 1-8 (1991)
17. DeVries VG, Schaffer SA, Largis EE, Dutia MD, Wang CH, Bloom JD and Katocs AS Jr: Potential antiatherosclerotic agents. 5. An acyl-CoA:cholesterol O-acyltransferase inhibitor with hypocholesterolemic activity. J Med Chem 29, 1131-1133 (1986)
18. Natori K, Okazaki Y, Nakajima T, Hirohashi T and Aono S: Mechanism of inhibition of cholesterol absorption by DL-melinamide: Inhibition of cholesterol esterification. Jpn J Pharmacol 42, 517-523 (1986)
19. Folch J, Lees M and Sloane SH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226, 497-509 (1957)
20. Cereijido M, Robbins ES, Dolan WJ, Rotunno CA and Sabatini DD: Polarized monolayers formed by epithelial cells on a permeable and translucent support. J Cell Biol 77, 853-880 (1978)
21. Fuller S, Bonsdorff CH and Simon K: Vesicular stomatitis virus infects and matures only through the basolateral surface of the polarized epithelial cell line, MDCK. Cell 38, 65-77 (1984)
22. Kashiwa M, Masuyama Y, Miyauchi H, Uchida T, Naganuma S, Kakuta H, Terada M, Kiriyama T, Matsuda K, Ito N et al: Pharmacological properties of YM-17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Jpn J Pharmacol 73, 41-50 (1997)
23. Ishida F, Sato A, Iizuka Y and Kamei T: Inhibition of acyl coenzyme A: cholesterol acyltransferase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Chem Pharm Bull (Tokyo) 37, 1635-1636 (1989)
24. Ishida F, Sato A, Iizuka Y, Kitani K, Sawasaki Y and Toshio K: Effects of MK-733 (simvastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on intestinal acylcoenzyme A:cholesterol acyltransferase activity in rabbits. Biochim Biophys Acta 1004, 117-123 (1989)
25. Sakuma Y, Hagihara H, Ohne K, Nagayoshi A, Mutoh S, Ito Y, Notsu Y and Okuhara M: Plasma cholesterol reducing effect of FR129169, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in the rat. Jpn J Pharmacol 70, 35-41 (1996)
26. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343, 425-430 (1990)
27. Sinensky M, Beck LA, Leonard S and Evans R: Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265, 19937-19941 (1990)
28. Wetterau JR and Zilversmit DB: Purification and characterization of microsomal triglyceride and cholesteryl ester transfer protein from bovine liver microsomes. Chem Phys Lipids 38, 205-222 (1985)
29. Wetterau JR and Zilversmit DB: Localization of intracellular triacylglycerol and cholesteryl ester transfer activity in rat tissues. Biochim Biophys Acta 875, 610-617 (1986)
30. Jiao S, Matsuzawa Y, Matsubara K, Kihara S, Kanamura T, Tokunaga K, Kubo M and Tarui S: Increased activity of intestinal acyl-CoA:cholesterol acyltransferase in rats with streptozotocin-induced diabetes and restoration by insulin supplementation. Diabetes 37, 342-346 (1988)
31. Jiao S, Matsuzawa Y, Matsubara K, Kubo M, Tokunaga K, Odaka H, Ikeda H, Matsuo T and Tarui S: Abnormalities of plasma lipoproteins in a new genetically obese rat with noninsulin-dependent diabetes mellitus (Wistar fatty rat). Int J Obes 15, 487-495 (1991)
32. Cavallero E, Dachet C, Neufcour D, Wirquin E, Mathe D and Jacotot B: Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: Relationship to postprandial lipemia and C-peptide / glucagon levels. Metabolism 43, 270-278 (1994)
33. Clifton PM: Postprandial lipoproteins and coronary heart disease. J Cardiovasc Risk 1, 197-201 (1994)